EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species

Ai Vu Hong iD, Laurence Suel, Eva Petat, Auriane Dubois, Pierre-Romain Le Brun iD, Nicolas Guerchet, Philippe Veron, Jérôme Poupiot, Isabelle Richard

Nature Communications · 11.09.2024 · 15 (1)

DOI: 10.1038/s41467-024-52002-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature Communications, online erschienen am 11.09.2024. Verfasst von Ai Vu Hong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Genethon, 1 bis rue de l'internationale, Evry, France. avuhong@genethon.fr. Hauptthemen laut MEDLINE: Dependovirus, Muscle, Skeletal, Genetic Therapy. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut National de la Santé et de la Recherche Médicale (National Institute of Health and Medical Research).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current adeno-associated virus (AAV) gene therapy using nature-derived AAVs is limited by non-optimal tissue targeting. In the treatment of muscular diseases (MD), high doses are often required but can lead to severe adverse effects. Here, we rationally design an AAV capsid that specifically targets skeletal muscle to lower treatment doses. We computationally integrate binding motifs of human integrin alphaV beta6, a skeletal muscle receptor, into a liver-detargeting capsid. Designed AAVs show higher productivity and superior muscle transduction compared to their parent. One variant, LICA1, demonstrates comparable muscle transduction to other myotropic AAVs with reduced liver targeting. LICA1's myotropic properties are observed across species, including non-human primate. Consequently, LICA1, but not AAV9, effectively delivers therapeutic transgenes and improved muscle functionality in two mouse MD models (male mice) at a low dose (5E12 vg/kg). These results underline the potential of our design method for AAV engineering and LICA1 variant for MD gene therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusMuscle, SkeletalGenetic TherapyAnimalsHumansMiceMaleGenetic VectorsIntegrinsCapsid ProteinsMuscular DiseasesTransduction, GeneticLiverCapsidReceptors, VitronectinDisease Models, AnimalHEK293 CellsTransgenesMice, Inbred C57BLAntigens, Neoplasm

Substanzen

integrin alphavbeta6IntegrinsCapsid ProteinsReceptors, VitronectinAntigens, Neoplasm

Autor:innen und Institutionen

  • Genethon, 1 bis rue de l'internationale, Evry, France. avuhong@genethon.fr.
  • INTEGRARE research unit UMR_S951 (INSERM, Université Paris-Saclay, Univ Evry), Evry, France. avuhong@genethon.fr.
  • Genethon, 1 bis rue de l'internationale, Evry, France.
  • INTEGRARE research unit UMR_S951 (INSERM, Université Paris-Saclay, Univ Evry), Evry, France.
  • Genethon, 1 bis rue de l'internationale, Evry, France. richard@genethon.fr.
  • INTEGRARE research unit UMR_S951 (INSERM, Université Paris-Saclay, Univ Evry), Evry, France. richard@genethon.fr.

ORCID-Profile: Ai Vu Hong, Pierre-Romain Le Brun

Förderung

  • Institut National de la Santé et de la Recherche Médicale (National Institute of Health and Medical Research)

Zitieren

APA

Vu Hong, A., Suel, L., Petat, E., Dubois, A., Le Brun, P. R., Guerchet, N., Veron, P., Poupiot, J., & Richard, I. (2024). An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-52002-4

Vancouver

Vu Hong A, Suel L, Petat E, Dubois A, Le Brun PR, Guerchet N, et al. An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species. Nature Communications. 2024;15(1). doi:10.1038/s41467-024-52002-4

BibTeX
@article{VuHong2024,
  author = {Vu Hong, Ai and Suel, Laurence and Petat, Eva and Dubois, Auriane and Le Brun, Pierre-Romain and Guerchet, Nicolas and Veron, Philippe and Poupiot, Jérôme and Richard, Isabelle},
  title = {An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species},
  journal = {Nature Communications},
  year = {2024},
  volume = {15},
  number = {1},
  doi = {10.1038/s41467-024-52002-4}
}
Kostenlos starten →